Harvard Bioscience, Inc. (HBIO)

Market Cap	94.20M
Revenue (ttm)	97.73M
Net Income (ttm)	-14.24M
Shares Out	43.61M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	24.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,255
Open	2.070
Previous Close	2.050
Day's Range	1.990 - 2.160
52-Week Range	1.990 - 5.560
Beta	1.31
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellula...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Dec 7, 2000
• Employees: 416
• Stock Exchange: NASDAQ
• Ticker Symbol: HBIO
• Website: https://www.harvardbioscience.com

Financial Performance

In 2023, Harvard Bioscience's revenue was $112.25 million, a decrease of -0.96% compared to the previous year's $113.34 million. Losses were -$3.42 million, -64.11% less than in 2022.